As of December 2014, there were 3 approved vaccines for human papillomavirus (HPV):
bivalent Cervarix (GlaxoSmithKline, New York, NY), quadrivalent Gardasil (Merck and Co …

Human papillomavirus (HPV) affects hundreds of millions of people worldwide and is
associated with both benign and malignant neoplasms in men and women. It is a double …

This report summarizes the epidemiology of human papillomavirus (HPV) and associated
diseases, describes the licensed HPV vaccines, provides updated data from clinical trials …

Abstract In October 2009, the Advisory Committee on Immunization Practices (ACIP)
approved a newly licensed vaccine, Cervarix®, directed against human papillomavirus …

On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human
papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 …

Since the discovery of the causal association between human papillomavirus (HPV) and
cervical cancer, efforts to develop an effective prophylactic vaccine to prevent high-risk HPV …

Recently, many studies have evaluated HPV vaccine safety and adverse effects. Two
vaccine shave been recently evaluated in randomized controlled trials: the bivalent vaccine …

Purpose. Human papillomavirus (HPV) disease and vaccines and several controversial
issues associated with vaccine administration are reviewed. Summary. HPV infection is the …

In 2006, the US Food and Drug Administration licensed the first vaccine against human
papillomavirus (HPV), Gardasil (Merck & Co). A second HPV vaccine, Cervarix …

Genital human papillomavirus (HPV) infection and HPV‐associated cervical and other
anogenital cancers are significant public health problems. HPV 16 and HPV 18 are …